VCYT Veracyte, Inc.
Healthcare$44.21-1.82%ClosedMarket Cap: $3.53B
As of 2026-05-26
Valuation
P/E (TTM)
38.50
PEG
0.22
P/B
2.66
P/S
6.63
EV/EBITDA
31.75
DCF Value
$40.02
FCF Yield
4.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
71.3%
Operating Margin
12.5%
Net Margin
16.2%
ROE
6.9%
ROA
6.1%
ROIC
4.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $139.1M | 72.3% | $23.8M | $28.7M | $— | — |
| Q4 null | $140.6M | 74.4% | $25.9M | $41.1M | $— | — |
| FY null | $517.1M | 69.6% | $74.2M | $66.4M | $— | — |
| Q3 null | $131.9M | 69.2% | $22.9M | $19.1M | $— | — |
| Q2 null | $130.2M | 69.0% | $-5.3M | $-980.0K | $— | — |
| Q1 null | $114.5M | 69.5% | $2.9M | $7.0M | $— | — |
| Q4 null | $118.6M | 66.4% | $4.2M | $5.1M | $— | — |
| FY null | $445.8M | 66.9% | $16.1M | $24.1M | $— | — |
| Q3 null | $115.9M | 68.2% | $12.0M | $15.2M | $— | — |
| Q2 null | $114.4M | 68.1% | $4.6M | $5.7M | $— | — |
| Q1 null | $96.8M | 64.5% | $-4.7M | $-1.9M | $— | — |
| Q4 2023 | $98.2M | 70.1% | $-35.5M | $-28.3M | $-0.39 | — |